NCT02836574Phase 2Completed

A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease

Study sponsor: Prokidney

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-12Actual

Enrollment · participants83Actual

Source updated2025-08-24Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Type 2 Diabetes Mellitus; Chronic Kidney Disease

Treatments or interventions studied

Renal Autologous Cell Therapy (REACT)BiologicalAlso known as Rilparencel

Primary outcomes · main study measures

Read the study measures

measure: Change in Renal Function; description: Serial measurements of estimated glomerular filtration rate (eGFR) obtained pre-randomization and at three-month intervals through 24 months after the last REACT injection in the active treatment group and at least 12 months post last REACT injection in the deferred treatment group.; timeFrame: Through 24 months following last REACT injection for active arm and at least 12 months following last REACT injection for the deferred arm

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history